Galderma’s offer for Q-Med: Offer document made public
This press release may not, directly or indirectly, be distributed or published in the United States, Australia, Japan, Canada, New Zealand, Hong Kong or South Africa. The offer is not being made to (and acceptances will not be accepted from) persons in those countries or elsewhere where their participation requires further documentation, filings or other measures in addition to those required by Swedish law.
Please click on the following link to see the full press release: http://bit.ly/fu5ZDe
(If the link is not clickable, copy and paste it into your browser.)
Galderma Pharma SA Galderma Holding AB
For additional information contact:
Peter Nicholson, Galderma
+33 676 22 71 18
Anders Fogel, Brunswick Group
+46 8 410 32 180
This information was submitted for publication on 3 January 2011 at 3:30 pm (CET).
About Galderma
Galderma’s ambition is to be recognized as the most competent and successful innovation-based company focused exclusively on meeting the needs of dermatology patients and physicians. A fully-integrated specialty pharmaceutical company, Galderma was founded in 1981 and has over 3000 employees actively collaborating with doctors, scientists, research institutes, universities, and patient advocacy groups who all share a commitment to improving the health of skin. With approximately 20% of sales invested each year to discover and develop new products and access innovative technologies, Galderma’s laboratory in Sophia-Antipolis, France, is one of the largest R&D facilities in the world dedicated exclusively to dermatology. The company’s extensive portfolio of products is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and skin senescence. Leading brands include Epiduo, Differin, Oracea, MetroGel, Cetaphil, Tetralysal, Loceryl, Clobex, Tri-Luma, Silkis, Vectical, Dysport, Azzalure and Emervel.